Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NJ1A
|
||||
| Former ID |
DNC008582
|
||||
| Drug Name |
Aloxistatin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89] | Discontinued in Phase 3 | [545202] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H30N2O5
|
||||
| Canonical SMILES |
CCOC(=O)C1C(O1)C(=O)NC(CC(C)C)C(=O)NCCC(C)C
|
||||
| InChI |
1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
|
||||
| InChIKey |
SRVFFFJZQVENJC-IHRRRGAJSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Calpain | Target Info | Inhibitor | [531262] | |
| Cathepsin G | Target Info | Inhibitor | [528870] | ||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Degradation of the extracellular matrixR-HSA-1474228:Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | |||||
| Metabolism of Angiotensinogen to Angiotensins | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| References | |||||
| Ref 528870 | J Biol Chem. 2007 Jul 20;282(29):20836-46. Epub 2007 May 29.Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. | ||||
| Ref 531262 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.